The comparison of effectiveness Estrofem, Kliogest, and Trisequens in women with surgical menopause

Abstract

The menopause is accompanied by changes of lipid profde and some parameters of hemostasis. These changes are results of estrogen deficiency and aging. Some women become menopausal in younger age, in premenopausal or reproductive period of their life, by surgical removal of ovaries with or without hysterectomy. We evaluate the serum concentrations of gonadotropins, sex steroids, cholesterol, triglicerids, LDL, HDL, fibrinogen in 66 women with surgical menopause and effectiveness of hormone replacement with estrofem, kliogest and trisequence. We used combined (continuous and sequential) therapy in those women after hysterectomy who underwent surgery because of endometriosis.

Full Text

Results. Estrofem and kliogest significantly decreased LH (mediana before treatment was 29,8 mlU/l and 19,5 and 17,2 respectively), FSH (75,1 mlU/l versus 30,2 and 28,6 respectively), trisequens didn’t change LH and FSH. Estradiol increased from 50 pmol/l to 493 (estrofem), 329 (kliogest) and 380 (trisequens). Testosteron and DHEAS were significantly higher after usage of estrofem, than before treatment or usage of kliogest and trisequens. These changes in hormonal pattern were accompanied by following changes in lipids and fibrinigen (mediana, ql-q2):

N=66	Before treatment	Estrofem n=26	Kliogest n=17	Trisequens n=23
Cholesterol mg/dl	219,5 (183.5-235.5)	199,0 (173.5-212.5)	195,0 (171.5-212.0)	201,5 (170.0-210.0)
Triglicerids mg/dl	95,0 (74.0-122,5)	101,5 (80.5-143,0)	76,0 (64,0-93.5)	75,0 (52.0-93.0)
LDL mg/dl	123,0 (102.0-154.0)	100,0 (86.5-112.5)	113,0 (92.0-121.0)	104,0 (80.5-124,5)
HDL mg/dl	63,0 (54.5-71.5)	67,0 (57.5-85,5)	64,0 (56,0-70.5)	75,0 (66.5-85.0)
Fibrinogen mg %	425,0 (350.0-500.0)	350,0 (287.5-475,0)	330,0 (312.5-425.0)	300,0 (250.0-300.0)

Thus, estrofem, kliogest and trisequens, decreasing levels of cholesterol, LDL and fibrinogen, reduce risk of cardiovascular disease in women with surgical menopause.